FDA Brief

Warning letters Drugs

FDA warning letter to

VeganicSKN Limited

High riskIssued Feb 9Posted Sep 29Center for Drug Evaluation and Research (CDER)

FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

What happened

FDA inspected VeganicSKN's drug manufacturing facility in Rocklea, Queensland, Australia, from July 15 to 21, 2025. FDA found the firm released and shipped a drug batch to the U.S. after an out-of-specification (OOS) test result - a result outside established limits - and did not determine a root cause. FDA also found the firm did not adequately test an incoming high-risk component for identity, accepted it based on the supplier's certificate of analysis, and used an expired lot.

What FDA found

  1. The company did not thoroughly investigate an out-of-specification test result before releasing and shipping the batch, and it did not determine a root cause.

    21 CFR 211.192
  2. The company did not perform at least one identity test on each incoming component lot and did not establish the reliability of supplier test results at appropriate intervals.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company used an expired component lot that was at high risk for contamination without adequate identity testing for hazardous impurities.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The quality unit did not adequately exercise its authority, including ensuring its roles and responsibilities were defined and that production personnel did not perform quality assurance functions.

    21 CFR 211.22(a) and 21 CFR 211.22(d)
  5. The company did not ensure production and process control procedures assured drug quality, including completion of bulk hold time validation studies.

    21 CFR 211.100(a)

What FDA wants

FDA tells VeganicSKN to respond in writing within 15 working days with corrective actions and the requested reviews, including a retrospective OOS review, high-risk component testing and risk assessment, and quality-unit remediation. FDA also placed all drugs and drug products offered for import from the firm on Import Alert 66-40 on January 9, 2026.

Who should pay attention

  • US importers and distributors of VeganicSKN drug products
  • companies that buy drug products from VeganicSKN
  • quality teams relying on supplier certificates of analysis for high-risk components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk